PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07047807

Acronym

PDAC-PATHWAYS

Enrollment

Registered

2025-07-02

Start date

2025-10-06

Completion date

2027-08-01

Last updated

2026-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PDAC - Pancreatic Ductal Adenocarcinoma

Brief summary

This study aims to refine and pilot test PDAC-PATHWAYS, a digital informational and supportive care app for patients who are initiating neoadjuvant therapy for pancreatic ductal adenocarcinoma (PDAC).

Detailed description

There are two parts of this study. Study Part 1 is an open pilot study to refine PDAC-PATHWAYS prior to larger-scale testing in a randomized controlled trial (RCT) setting. Study Part 1 is purely descriptive, as the investigators will use the data to refine PDAC-PATHWAYS before proceeding to Study Part 2. Study Part 2 is a pilot RCT to assess the feasibility and acceptability of conducting a randomized trial of PDAC-PATHWAYS versus usual care. Participants will complete a baseline survey and then be randomized to PDAC-PATHWAYS versus usual care. This record reflects the clinical trial component (Study Part 2), as feasibility and acceptability outcomes will be collected for this phase only.

Interventions

BEHAVIORALPDAC-PATHWAYS

A digital app for patients initiating neoadjuvant therapy for PDAC

OTHERUsual Care

Routine treatment

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age≥18 years * Within 8 weeks of a documented decision to pursue neoadjuvant therapy for newly diagnosed, non-metastatic PDAC * Able to comprehend and speak English

Exclusion criteria

* Comorbid health condition that would interfere with study participation, as identified by the cancer care team

Design outcomes

Primary

Measure	Time frame	Description
Feasibility: Enrollment rate	10 weeks	≥50% enrollment among consecutive eligible patients
Feasibility: intervention completion rate	10 weeks	≥50% completion of at least four app modules among those assigned to the intervention

Secondary

Measure	Time frame	Description
Acceptability	10 weeks	≥70% of patients in the intervention arm reporting Client Satisfaction Questionnaire-8 scores at or above the midpoint score of 20 on a scale from 8-32 (higher scores indicate higher satisfaction)

Countries

United States

Contacts

CONTACTKelsey Lau-Min, MD, MSCE

klau-min@mgh.harvard.edu617-724-4000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 30, 2026